Generation and characterisation of human saphenous vein endothelial cell lines.
Primary human endothelial cells have a finite life span in vitro. After 3-4 passages, they tend to de-differentiate and eventually reach senescence. This limits their use in studies of endothelial cell function. To overcome this, we have developed human saphenous vein endothelial cell lines (HSVEC lines). Two cell lines were produced by infection with pZipSVtsA58-U19 which encodes the simian virus 40 large T-antigen, and one cell line was obtained by transfection with pLXSN16E6E7, which encodes the human papillomavirus type 16 E6 and E7 genes. Two of the three HSVEC lines exhibited an extended life span in vitro and retained characteristic endothelial "cobblestone" morphology. These cell lines expressed the known endothelial markers CD31 and vascular endothelial cadherin, and were able to bind Ulex europaeus lectin I, but they did not retain the expression of von Willebrand factor. Furthermore, one cell line was able to functionally up-regulate the expression of intercellular adhesion molecule-1 in response to stimulation with tumor necrosis factor alpha and was also able to incorporate acetylated low-density lipoprotein. Our results suggest that this latter HSVEC line will provide a useful resource to investigate selected responses of the vascular endothelium to physiological and pathological situations.
Scoumanne
Ariane
A
Department of Vascular Surgery, Division of Surgery, Anaesthesia and Intensive Care, Imperial College School of Medicine, Charing Cross Hospital Campus, Fulham Palace Road, London W6 8RF, UK. a.scoumanne@ic.ac.uk
Kalamati
Tahereh
T
Moss
Jill
J
Powell
Janet T
JT
Gosling
Martin
M
Carey
Nessa
N
D000906:Antibodies / Q000276:immunology; D015703:Antigens, CD; D000957:Antigens, Viral, Tumor / Q000096:biosynthesis / Q000276:immunology; D015820:Cadherins; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000166:cytology* / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis / Q000187:drug effects; D007375:Interleukin-1 / Q000494:pharmacology; D008077:Lipoproteins, LDL / Q000494:pharmacology; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D012190:Retroviridae / Q000276:immunology; D012192:Retroviridae Infections / Q000276:immunology; D012501:Saphenous Vein / Q000166:cytology* / Q000378:metabolism*; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D015854:Up-Regulation / Q000187:drug effects; D014841:von Willebrand Factor / Q000096:biosynthesis; D000099152:Cadherin 5
D000906:Antibodies; D015703:Antigens, CD; D000957:Antigens, Viral, Tumor; D015820:Cadherins; D018799:Intercellular Adhesion Molecule-1; D007375:Interleukin-1; D008077:Lipoproteins, LDL; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D014409:Tumor Necrosis Factor-alpha; D014841:von Willebrand Factor; D000099152:Cadherin 5; C032629:acetyl-LDL